MLex Comment: Pfizer, Wyeth deal may not cause sizeable antitrust concerns
Pfizer’s announcement that it will acquire rival drug-maker Wyeth appears unlikely, at first glance, to pose the European Commission any sizeable antitrust concerns meaning that a Phase I clearance, possibly with...To view the full article, register now.
Already a subscriber? Click here to view full article